In a retrospective analysis of adults with a BMI of 40 kg/m 2 or higher who were prescribed once-weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk), those who previously underwent bariatric surgery and did not lose a sufficient amount of weight or regained weight after the procedure lost 9.8% of their body weight at 24 weeks and achieved an excess weight loss of 23.2%
GLP-1 has been shown to produce significant weight loss results in clinical trials, with patients experiencing both physical and psychological benefits
Wszystkie wyej wymienione waciwoci obserwuje si przy badaniach laboratoryjnych, nierobione na ludziach, maj one charakter wycznie informacyjny
First, the stepwise increase in weight loss as additional receptor mechanisms are added (GLP-1 only to GLP-1+GIP to GLP-1+GIP+glucagon) is consistent with the additive-mechanism hypothesis that underpinned the retatrutide program
It carries metabolic consequences
They show a loss of efficacy